Compare Novartis AG (NVS) vs Oklo Inc (OKLO) Price & Performance

Novartis AGTrade

Oklo IncTrade

Price performance (Past 24H)

Key statistics

Novartis AG vs Oklo Inc — how do they compare? Novartis AG trades at $153.53 (market cap $298.18B), while Oklo Inc trades at $47.56 (market cap $8.28B). The key difference: Novartis AG is far larger — about 36× Oklo Inc's market cap, and Novartis AG pays a 3.02% dividend while Oklo Inc pays none. Which is the better fit depends on your goals.

	NVS	OKLO
Market Cap	$298.18B	$8.28B
Sector	Health	Technology
52-Week High	$168.62	$174.14
52-Week Low	$119.31	$36.84
Enterprise Value	$339.50B	$5.81B
Dividend Yield	3.02%	—

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Novartis AG

No Aura AI signal available yet.

Oklo Inc

OKLO trades at $48.42, up 14.77% in the past 24 hours, with a bullish technical signal and strong analyst consensus. The stock is supported by recent milestones, including the Groves reactor achieving first criticality and reporting its first meaningful revenue of $1.2 million in Q2 2026, though it posted a wider net loss. The company maintains substantial liquidity of approximately $2.5 billion as of March 2026, supporting its aggressive development plans.

The outlook is optimistic due to strong institutional backing and growth potential in the nuclear energy sector, but significant execution risks and persistent losses pose challenges. The consensus price target of $82.69 suggests substantial upside if operational milestones are met, yet the high cash burn and unproven business model warrant caution for investors.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

NVS

BioCryst hits profitability with strong Q2 revenue, sparking takeover interest in rare disease biotech.24/7 Wall Street · 1 day agoBullish New report analyzes 1,350+ precision medicine deals from 2019-2026, revealing market trends and deal structures.Researchandmarkets.Com · 4 days agoNeutral View details →

OKLO

NuScale Power shares fall 32% YTD amid revenue drop and dilution, awaiting key contracts to rebound.24/7 Wall Street · 19 hours agoBearish Oklo posts first revenue with reactor milestone; AST SpaceMobile reports higher revenue but heavy launch loss.24/7 Wall Street · 23 hours agoNeutral Oklo posts $1.2M Q2 revenue with 14% stock rise, but core tech validation and cost clarity remain uncertain.Seeking Alpha · 3 days agoNeutral View details →

About Novartis AG

Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.

About Oklo Inc

Oklo Inc. is a company focused on developing and commercializing advanced fission power plants. The company specializes in micro-reactor technology, specifically the Aurora design, which uses advanced fuel to produce reliable, clean, and cost-competitive power. Oklo aims to provide scalable, on-site power solutions to various customers, including remote communities, industrial facilities, and government entities, positioning itself as an innovator in the next generation of nuclear energy.